Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02895945 · ClinicalTrials.gov registry record · Phase 3
BAX 802 in CHA With Inhibitors
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT02895945 is a Phase 3 study that was terminated before completion, run by Baxalta now part of Shire. The registered enrollment target is 8 participants.
The verdict
NCT02895945, a Phase 3 study, was terminated before completion, sponsored by Baxalta now part of Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective surgical, dental, or other invasive procedures.
Interventions
- BIOLOGICAL Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2021-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02895945
The ClinicalTrials.gov registry entry for NCT02895945 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802) is the first listed.
NCT02895945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02895945 about?
NCT02895945 is a clinical study titled "BAX 802 in CHA With Inhibitors". The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective surgical, dental, or other invasive procedures.
What is the current status of trial NCT02895945?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2016-12-22. Estimated completion is 2021-01-22.
What interventions are being tested in trial NCT02895945?
The interventions under investigation include: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02895945?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.